

Proceeding Paper

Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants [†]

Edgar Clyde R. Lopez ^{1,2} 

¹ Nanotechnology Research Laboratory, Department of Chemical Engineering, University of the Philippines Diliman, Quezon City 1000, Philippines; edgarclodelopez09@gmail.com

² Department of Chemical Engineering, University of Santo Tomas, España Blvd., Sampaloc, Manila 1015, Philippines

[†] Presented at the 4th International Electronic Conference on Applied Sciences, 27 October–10 November 2023; Available online: <https://asec2023.sciforum.net/>.

Abstract: SARS-CoV-2 caused the ongoing COVID-19 pandemic, and only a few treatment options are available to mitigate its impact on human health. Hence, there is a need to discover drugs that could be used to treat COVID-19. Several studies have already reported the repurposing of existing drugs to inhibit the receptor-binding domain of SARS-CoV-2. However, the emergence of COVID-19 variants may render current drug candidates ineffective. Here, we report the structure-based drug screening of the DrugBank database against the wild-type, B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2. Our study revealed that Salmeterol, Abediterol, and Lysophosphatidylglycerol are among the top candidates against all four variants. Furthermore, we showed that Salmeterol forms a stable complex with the receptor binding domain of SARS-CoV-2 variants. Further studies are needed to evaluate the clinical relevance of the drug candidates discovered. Nevertheless, this study provides insight into computational drug design that works against multiple variants of SARS-CoV-2.

Keywords: SARS-CoV-2; COVID-19; structure-based drug design; drug repurposing; molecular dynamics

1. Introduction

Since the declaration of a global pandemic by the World Health Organization (WHO) [1], COVID-19 has caused an unprecedented disruption in our daily lives, claiming millions of lives due to complications. While vaccination efforts have successfully prevented COVID-19 in real-world conditions [2], people still experience mild to moderate symptoms when infected by the virus during breakthrough infections [3]. To date, only Molnupiravir [4] and the combination drugs Nirmatrelvir/Ritonavir (Paxlovid) [5] have been granted emergency use authorization for COVID-19 treatment by the Philippine Food and Drugs Authority. However, while generally safe, these drugs are still not widely accessible due to supply chain limitations. Thus, there remains a need to discover drugs that could potentially treat COVID-19 infection.

Several strategies may be followed to discover new pharmaceutical compounds. Structure-based drug design uses a database of potential drugs to discover lead compounds based on their docking score [6]. Since it is based on a database of known molecules, drug discovery using this method heavily relies on the database's quality. Meanwhile, de novo drug design relies on the shape of the binding site to map out the chemical space for possible drug candidates using deep generative models [7]. While it can generate excellent ligands, it sometimes has the disadvantage of producing difficult-to-synthesize drug-like molecules.

While several studies have already been carried out in the search for inhibitors of SARS-CoV-2 [8–12], these studies only used the wild-type SARS-CoV-2 variant for drug screening. It is well-known that SARS-CoV-2 has mutated into several variants, such as the B.1.1.7,



Citation: Lopez, E.C.R.

Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants.

Eng. Proc. **2023**, *56*, 191. <https://doi.org/10.3390/ASEC2023-15536>

Academic Editor: Gianrico Spagnuolo

Published: 31 October 2023



Copyright: © 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

B.1.351, and P.1 variants, which were shown to evade immunity [13–16] and caused spikes in COVID-19 cases. To have a “universal drug” that could be used for COVID-19 treatment regardless of the variant involved, we performed a computational structure-based drug design study against the receptor binding domain (RBD) of SARS-CoV-2.

2. Computational Details

2.1. Target Preparation

The Protein Data Bank provided the high-resolution crystal structure of the receptor-binding domain (RBD) of SARS-CoV-2 spike protein (PDB 6MOJ) [17]. Its structure was altered with the relevant amino acid alterations for each SARS-CoV-2 variant. All four structures are then pre-processed to obtain their minimum-energy configurations, which were then employed in further docking computations. Missing hydrogens were specifically added, correct bond orderings were validated and assigned, accurate protonation states were predicted, and hydrogen bonds were optimized using systematic and cluster-based techniques. Restrained minimization was also used to relax bonds, angles, and overlaps within each structure.

2.2. Screening of FDA-Approved, Investigational, and Experimental Drugs

The e-LEA3D web server [18], which employs the LEA3D method created by Douguet et al. [19], was used to execute structure-based drug design. With a binding site radius of 20 Å, the RBD binding site is described as the region surrounding the centroid of the following amino acids: N501, Q498, E484, T470, L452, N439, P499, Q493, F486, A475, and L455 [20]. FDA-approved (2356), investigational (2424), and experimental (5962) medicines were evaluated for their ability to block the target binding site. DrugBank (release version 5.1.8) was used to retrieve these libraries [21]. Both the protein and the medication molecules are thought to be adaptable. Lipinski’s Rule of Five [22] was utilized as a limitation to assure that the compounds created will be drug-like [23]. A docking score was calculated based on the drug molecules’ binding to the protease’s binding pocket. Virtual screening was carried out against SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1. The docking scores of the therapeutic molecules against each SARS-CoV-2 variant were averaged and then sorted in order to identify the best-performing medicines capable of inhibiting all four forms.

2.3. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Study

The ADMET profiles of all performing drug candidates against the RBD of SARS-CoV-2 were evaluated using the ADMETlab 2.0 platform [24]. Only those that met the following criteria were considered promising candidate molecules: good human intestinal absorption ($p = 0.7$), low probability of passing through the blood–brain barrier ($p = 0.7$), good drug clearance (CL 5), low hERG toxicity ($p = 0.3$), low hepatotoxicity ($p = 0.3$), low probability of drug-induced liver damage ($p = 0.3$), low mutagenicity ($p = 0.3$), low acute toxicity ($p = 0.3$), and low carcinogenicity ($p = 0.3$).

2.4. Molecular Dynamics Calculations

The dynamical unbinding process and the manner of ligand–protein interactional binding were explored using molecular dynamics calculations on the top-performing ligand from structure-based drug design. For each protein–ligand complex structure, the calculations were carried out using the Ligand and Receptor Molecular Dynamics (LARMD) website [25].

3. Results and Discussion

3.1. Screening of FDA-Approved Drugs

Drug-repurposing of FDA-approved drugs is the fastest way to look for possible therapies against SARS-CoV-2 since they are already proven safe for use in human beings. Some researchers have done a virtual screening of FDA-approved drugs against the RBD

of SARS-CoV-2 in hopes of finding a potential inhibitor to prevent viral entry into the host cells [26–31]. However, those studies focused on the wild-type SARS-CoV-2. The fast emergence of new SARS-CoV-2 variants threatens drug development as the drug candidates previously identified may not be effective when used against the new variants. While we can continually develop new inhibitors for the new COVID-19 variants, this approach is resource-intensive. Instead, we screened 2356 FDA-approved drugs for their inhibitory effect against all four SARS-CoV-2 variants. This excludes illicit drugs and those already withdrawn from the market during our drug screening. We then averaged the docking scores of the drugs and identified the top 30 drugs that can potentially inhibit all four variants of SARS-CoV-2 (Table S1). The drugs we identified are currently being used to treat ocular hypertension, chronic obstructive pulmonary disease, erectile dysfunction, hypertension, and overactive bladder syndrome, among other conditions. As expected, most FDA-approved drugs have lower docking scores against B.1.1.7, B.1.351, and P.1 variants than wild-type SARS-CoV-2.

Overall, only 730 drugs met our ADMET criteria, i.e., having high human intestinal absorption, low blood–brain barrier permeation probability, and low toxicity. Only 11 drugs met these criteria among those we identified as top-performing drugs (Table S2). Among them are Latanoprost, Bimatoprost, Salmeterol, Carboprost tromethamine, Tafluprost, Vilanterol, Dopexamine, Labetalol, Silodosin, Trepstinil, and Propafenone.

Because COVID-19 presents a more severe illness in people with comorbidities such as chronic lung disease and hypertension, our discussion will focus more on drugs already being used to treat these diseases. Specifically, Salmeterol is a long-acting β_2 -adrenergic agonist (LABA) used to treat chronic obstructive pulmonary disease (COPD), chronic bronchitis, and asthma. Figure S1 shows the interaction of Salmeterol with the receptor-binding domain of various variants of SARS-CoV-2. Here, we see that the interaction of Salmeterol's phenol ring with the phenol ring of Tyr 505 via π - π stacking in wild-type SARS-CoV-2 was conserved in the B.1.1.7 and P.1 variants but not the B.1.351 variant. Instead, the π - π interaction occurs between the benzene ring of Salmeterol and the phenyl ring of the B.1.351 variant. The introduction of the N501Y mutation in the RBD of the B.1.1.7, B.1.351, and P.1 variants caused the appearance of a π - π interaction between the phenyl ring of Tyr 501 and Salmeterol. In addition, Salmeterol forms hydrogen bonds between its secondary hydroxyl and amine groups with the carbonyl group of Gly 496 in wild-type SARS-CoV-2. This hydrogen bond is lost in the new COVID-19 variants. Instead, new interactions appeared between Salmeterol and the new COVID-19 variants. In particular, the amino and carbonyl groups of Ser 494 and the carbonyl group of Leu 492 form hydrogen bonds with the hydroxyl group and the hydroxymethyl group of Salmeterol, respectively, in the B.1.1.7 variant.

Meanwhile, the amine and secondary hydroxyl groups form a hydrogen bond with the carbonyl group of Ser 494 in the B.1.351 variant. Moreover, the phenol ring of Salmeterol interacts with the phenol ring of Tyr 449 via π - π stacking in the B.1.351 variant. Conversely, the benzene ring of Salmeterol interacts with the phenol ring of Tyr 449 in the P.1 variant. Lastly, the hydroxymethyl group of Salmeterol forms a hydrogen bond with the amine group of Gln 498 in the B.1.351 variant but with the amine group of Gly 502 in the P.1 variant.

3.2. Screening of Investigational Drugs

We also screened the DrugBank database for potential inhibitors of the RBD of SARS-CoV-2 variants. Investigational drugs are those that have already entered clinical trials for a specific indication. Since a drug can have multiple statuses, e.g., an approved drug being studied for a different indication, we trimmed down the database by removing redundant entries already present in the database of FDA-approved drugs. A total of 2424 investigational drugs were screened, and the top-performing drugs were determined by ranking the average docking scores of the drugs across all four variants (Table S3). Among these, Abediterol came to our attention since it is currently being studied to treat

chronic obstructive pulmonary disease (COPD) and asthma and it has good ADMET profile (Table S4).

Figure S2 shows the interaction of Abediterol with the receptor-binding domain of various variants of SARS-CoV-2. Abediterol forms a hydrogen bond between its secondary amine group and the carbonyl group of Ser 494 in wild-type SARS-CoV-2. This hydrogen bond is conserved in the B.1.351 variant but not in the B.1.1.7 and the P.1 variants. An additional hydrogen bond is seen between the phenol group of Abediterol and the carbonyl group of Tyr 505. At the same time, Abediterol's pyridine ring interacts with the phenol ring of Tyr 505 via π - π stacking. Unfortunately, these interactions are not conserved in the new variants of COVID-19. New π - π interactions are seen between the phenyl ring of Tyr 501 and Tyr 505 and the benzene ring of Abediterol in the B.1.1.7, B.1.351, and P.1 variants. π - π stacking is also seen between the phenyl ring and the pyridinone ring of Abediterol with the phenol ring of Tyr 449 in the B.1.351 variant. New hydrogen bonds also emerged in the new COVID-19 variants. The carboxyl group of Glu 406 in B.1.1.7 forms a hydrogen bond with the secondary hydroxyl group of Abediterol. Lastly, the carbonyl group in the side chain of Gln 493 in the P.1 variant forms a hydrogen bond with the phenol group of Abediterol.

3.3. Screening of Experimental Drugs

We further expanded our search for potential inhibitors of the RBD of SARS-CoV-2 by screening the database of experimental drugs obtained from DrugBank. Experimental drugs are those which are being researched pre-clinically but have not yet entered formal clinical trials. Again, we removed the drugs overlapping with the FDA-approved and investigational drugs databases to prevent redundancy. A total of 5962 drugs were included in the trimmed database. The averaged values of the docking scores of each drug across all four variants were ranked to determine the top-performing inhibitors (Table S5). Among these, Lysophosphatidylglycerol emerged as the top candidate with excellent ADMET profile (Table S6). Lysophosphatidylglycerol is a lipid-like molecule belonging to a family of glycerophosphoglycerols are molecules containing a glycerol moiety attached to the phosphate group linked to a glycerol. The fatty acid in Lysophosphatidylglycerol is bonded to the glycerol moiety through an ester linkage.

Figure S3 shows the interaction of Lysophosphatidylglycerol with the RBD of SARS-CoV-2 variants. The wild-type SARS-CoV-2 forms five hydrogen bonds with Lysophosphatidylglycerol. The carbonyl and amine group of Ser 494 form a hydrogen bond with the terminal secondary hydroxyl group and the ester group of Lysophosphatidylglycerol. The amino and carbonyl groups of Gly 496 form a hydrogen bond with the ester group of Lysophosphatidylglycerol. Finally, the terminal primary hydroxyl group of Lysophosphatidylglycerol is involved in two hydrogen bonds: with the amine group of Asn 501 and the carbonyl group of Gly 496. However, these interactions are not conserved in the new COVID-19 variants.

Lysophosphatidylglycerol forms four hydrogen bonds with the B.1.1.7 variant: its phosphate group with the phenol group of Tyr 453 and the primary amine group of Arg 403, its hydroxyl group with the carbonyl group of Gly 496, and its terminal primary hydroxyl group with the primary amine group of Arg 403. Conversely, Lysophosphatidylglycerol forms five hydrogen bonds with the B.1.352 variant: its terminal hydroxyl group with the amine group of Gln 409, its carbonyl group with the phenol group of Tyr 453, its terminal hydroxyl group with the carboxylic group of the side chain of Glu 406, and the phosphate group with the primary amine group and the imide group of Arg 403. A salt bridge also exists between the phosphate group of Lysophosphatidylglycerol and the imide group of Arg 403. Conversely, only two hydrogen bonds are formed between Lysophosphatidylglycerol and the P.1 variant: its terminal primary hydroxyl group with the carbonyl group of Tyr 449 and its phosphate group with the amino group of Ser 494.

3.4. Molecular Dynamics Study

Molecular dynamics simulations were performed on Salmeterol to investigate its interaction with the SARS-CoV-2 variants further. Salmeterol forms a stable ligand–receptor complex with the RBD of all SARS-CoV-2 variants. Principal component analysis for the ligand binding and unbinding process (Figures S4 and S5 for wild type, Figures S6 and S7 for B.1.1.7 variant, Figures S8 and S9 for B.1.351 variant, and Figures S10 and S11 for P.1 variant) and dynamic cross-correlation analysis of the ligand binding and unbinding process (Figure S12 for wild type, Figure S13 for B.1.1.7 variant, Figure S14 for B.1.351 variant, and Figure S15 for P.1 variant) demonstrated the stability of the docked Salmeterol, indicating that it could inhibit the function of the RBD during SARS-CoV-2 pathogenesis. Moreover, we found that the average ligand RMSD in wild SARS-CoV-2 ($2.8430 \pm 0.8432 \text{ \AA}$) is comparable to that of the B.1.1.7 variant ($4.3099 \pm 1.0177 \text{ \AA}$), B.1.351 variant ($2.7488 \pm 0.7182 \text{ \AA}$), and P.1 variant ($1.9985 \pm 0.4290 \text{ \AA}$). The binding energy of the wild-type SARS-CoV-2 (-10.81 kcal/mol), B.1.1.7 variant (-13.10 kcal/mol), B.1.351 variant (-12.85 kcal/mol), and P.1 variant (-12.60 kcal/mol) were calculated using MMPBSA approach. These results show that Salmeterol acts against the wild-type SARS-CoV-2 and is also stable against other variants.

4. Conclusions

Structure-based drug design was carried out by screening the library of FDA-approved, experimental, and investigational drugs in the DrugBank database as possible inhibitors of four variants of SARS-CoV-2. The corresponding docking scores for each variant were average, and the ligands were then ranked. Among the drugs in the database, Salmeterol, Abediterol, and Lysophosphatidylglycerol emerged as top candidates against all four variants with a desirable ADMET profile. In particular, Salmeterol, a drug used for chronic obstructive pulmonary disease, interacts well with the RBD of SARS-CoV-2 by hydrogen bonding and π - π stacking. Molecular dynamics showed that Salmeterol forms a stable complex with the RBD with good binding energies against all four variants. As such, Salmeterol may be repurposed as a treatment for SARS-CoV-2 infection. Further studies are needed to ascertain the efficacy and safety of using these repurposed drugs for COVID-19 treatment.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ASEC2023-15536/s1>, **Table S1.** Comparative performance of top-performing FDA-approved drugs as potential inhibitors of the RBD of SARS-CoV-2 variants; **Figure S1.** Structures of Salmeterol, the top-performing FDA-approved drug, docked in the RBD of SARS-CoV-2 and their corresponding ligand interaction diagrams: (a,b) Wild type; (c,d) B.1.1.7 variant; (e,f) B.1.351 variant; and (g,h) P.1 variant; **Table S2.** ADMET properties of top-performing FDA-approved drugs as potential inhibitors of the RBD of SARS-CoV-2 variants; **Table S3.** Comparative performance of top-performing investigational drugs as potential inhibitors of the RBD of SARS-CoV-2 variants; **Figure S2.** Structures of Abediterol, the top-performing investigational drug, docked in the RBD of SARS-CoV-2 and their corresponding ligand interaction diagrams: (a,b) Wild type; (c,d) B.1.1.7 variant; (e,f) B.1.351 variant; and (g,h) P.1 variant; **Table S4.** ADMET properties of top-performing investigational drugs as potential inhibitors of the RBD of SARS-CoV-2 variants; **Table S5.** Comparative performance of top-performing experimental drugs as potential inhibitors of the RBD of SARS-CoV-2 variants; **Figure S3.** Structures of Lysophosphatidylglycerol, the top-performing experimental drug, docked in the RBD of SARS-CoV-2 and their corresponding ligand interaction diagrams: (a,b) Wild type; (c,d) B.1.1.7 variant; (e,f) B.1.351 variant; and (g,h) P.1 variant; **Table S6.** ADMET properties of top-performing experimental drugs as potential inhibitors of the RBD of SARS-CoV-2 variants; **Figure S4.** (a) Principal Component Analysis (PCA) for the MD trajectory of Salmeterol binding into Wild-type RBD; **Figure S5.** (a) Principal Component Analysis (PCA) for the MD trajectory of the unbinding process between Salmeterol and Wild-type RBD; **Figure S6.** (a) Principal Component Analysis (PCA) for the MD trajectory of Salmeterol binding into SARS-CoV-2 B.1.1.7 Variant RBD; **Figure S7.** (a) Principal Component Analysis (PCA) for the MD trajectory of the unbinding process between Salmeterol and SARS-CoV-2 B.1.1.7 RBD;

Figure S8. (a) Principal Component Analysis (PCA) for the MD trajectory of Salmeterol binding into SARS-CoV-2 B.1.351 Variant RBD; **Figure S9.** (a) Principal Component Analysis (PCA) for the MD trajectory of the unbinding process between Salmeterol and SARS-CoV-2 B.1.351 RBD; **Figure S10.** (a) Principal Component Analysis (PCA) for the MD trajectory of Salmeterol binding into SARS-CoV-2 P.1 Variant RBD; **Figure S11.** (a) Principal Component Analysis (PCA) for the MD trajectory of the unbinding process between Salmeterol and SARS-CoV-2 P.1 RBD; **Figure S12.** Dynamical residue cross-correlation map for the MD trajectory of the (a) binding process and (b) unbinding process of the receptor-ligand complex involving Salmeterol docked in Wild-type RBD; **Figure S13.** Dynamical residue cross-correlation map for the MD trajectory of the (a) binding process and (b) unbinding process of the receptor-ligand complex involving Salmeterol docked in SARS-CoV-2 B.1.1.7 RBD; **Figure S14.** Dynamical residue cross-correlation map for the MD trajectory of the (a) binding process and (b) unbinding process of the receptor-ligand complex involving Salmeterol docked in SARS-CoV-2 B.1.351 RBD; **Figure S15.** Dynamical residue cross-correlation map for the MD trajectory of the (a) binding process and (b) unbinding process of the receptor-ligand complex involving Salmeterol docked in SARS-CoV-2 P.1 RBD.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the Supplementary Material.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Sohrabi, C.; Alsafi, Z.; O'Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int. J. Surg.* **2020**, *76*, 71–76. [[CrossRef](#)] [[PubMed](#)]
- Thompson, M.G.; Burgess, J.L.; Naleway, A.L.; Tyner, H.; Yoon, S.K.; Meece, J.; Olsho, L.E.W.; Caban-Martinez, A.J.; Fowlkes, A.L.; Lutrick, K.; et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *N. Engl. J. Med.* **2021**, *385*, 320–329. [[CrossRef](#)] [[PubMed](#)]
- Bergwerk, M.; Gonen, T.; Lustig, Y.; Amit, S.; Lipsitch, M.; Cohen, C.; Mandelboim, M.; Levin, E.G.; Rubin, C.; Indenbaum, V.; et al. COVID-19 Breakthrough Infections in Vaccinated Health Care Workers. *N. Engl. J. Med.* **2021**, *385*, 1474–1484. [[CrossRef](#)] [[PubMed](#)]
- Bernal, A.J.; da Silva, M.M.G.; Musungaie, D.B.; Kovalchuk, E.; Gonzalez, A.; Reyes, V.D.; Martín-Quirós, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M.L.; et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N. Engl. J. Med.* **2022**, *386*, 509–520. [[CrossRef](#)] [[PubMed](#)]
- Rahmah, L.; Abarikwu, S.O.; Arero, A.G.; Essouma, M.; Jibril, A.T.; Fal, A.; Flisiak, R.; Makuku, R.; Marquez, L.; Mohamed, K.; et al. Oral antiviral treatments for COVID-19: Opportunities and challenges. *Pharmacol. Rep.* **2022**, *74*, 1255–1278. [[CrossRef](#)] [[PubMed](#)]
- Bajad, N.G.; Rayala, S.; Gutti, G.; Sharma, A.; Singh, M.; Kumar, A.; Singh, S.K. Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. *Curr. Res. Pharmacol. Drug Discov.* **2021**, *2*, 100026. [[CrossRef](#)] [[PubMed](#)]
- Li, Y.; Pei, J.; Lai, L. Structure-based: De novo drug design using 3D deep generative models. *Chem. Sci.* **2021**, *12*, 13664–13675. [[CrossRef](#)] [[PubMed](#)]
- Amin, S.A.; Banerjee, S.; Ghosh, K.; Gayen, S.; Jha, T. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. *Bioorg. Med. Chem.* **2021**, *29*, 115860. [[CrossRef](#)]
- Ngo, S.T.; Pham, N.Q.A.; Le, L.T.; Pham, D.H.; Vu, V.V. Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease. *J. Chem. Inf. Model.* **2020**, *60*, 5771–5780. [[CrossRef](#)]
- Shan, H.; Liu, J.; Shen, J.; Dai, J.; Xu, G.; Lu, K.; Han, C.; Wang, Y.; Xu, X.; Tong, Y.; et al. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. *Cell Chem. Biol.* **2021**, *28*, 855–865.e9. [[CrossRef](#)]
- Li, S.; Wang, L.; Meng, J.; Zhao, Q.; Zhang, L.; Liu, H. De Novo design of potential inhibitors against SARS-CoV-2 Mpro. *Comput. Biol. Med.* **2022**, *147*, 105728. [[CrossRef](#)] [[PubMed](#)]
- Dai, W.; Zhang, B.; Jiang, X.-M.; Su, H.; Li, J.; Zhao, Y.; Xie, X.; Jin, Z.; Peng, J.; Liu, F.; et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. *Science* **2020**, *368*, 1331–1335. [[CrossRef](#)] [[PubMed](#)]
- Zhou, D.; Dejnirattisai, W.; Supasa, P.; Liu, C.; Mentzer, A.J.; Ginn, H.M.; Zhao, Y.; Duyvesteyn, H.M.E.; Tuekprakhon, A.; Nutalai, R.; et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* **2021**, *184*, 2348–2361.e6. [[CrossRef](#)] [[PubMed](#)]

14. Hoffmann, M.; Arora, P.; Groß, R.; Seidel, A.; Hörnich, B.F.; Hahn, A.S.; Krüger, N.; Graichen, L.; Hofmann-Winkler, H.; Kempf, A.; et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell* **2021**, *184*, 2384–2393.e12. [[CrossRef](#)] [[PubMed](#)]
15. Wang, P.; Nair, M.S.; Liu, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P.D.; et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **2021**, *593*, 130–135. [[CrossRef](#)] [[PubMed](#)]
16. Harvey, W.T.; Carabelli, A.M.; Jackson, B.; Gupta, R.K.; Thomson, E.C.; Harrison, E.M.; Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S.J.; et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat. Rev. Microbiol.* **2021**, *19*, 409–424. [[CrossRef](#)] [[PubMed](#)]
17. Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **2020**, *581*, 215–220. [[CrossRef](#)]
18. Douguet, D. e-LEA3D: A computational-aided drug design web server. *Nucleic Acids Res.* **2010**, *38*, 615–621. [[CrossRef](#)]
19. Douguet, D.; Munier-Lehmann, H.; Labesse, G.; Pochet, S. LEA3D: A computer-aided ligand design for structure-based drug design. *J. Med. Chem.* **2005**, *48*, 2457–2468. [[CrossRef](#)]
20. Yi, C.; Sun, X.; Ye, J.; Ding, L.; Liu, M.; Yang, Z.; Lu, X.; Zhang, Y.; Ma, L.; Gu, W.; et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cell. Mol. Immunol.* **2020**, *17*, 621–630. [[CrossRef](#)]
21. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; et al. DrugBank 5.0: A major update to the DrugBank database for 2018. *Nucleic Acids Res.* **2018**, *46*, D1074–D1082. [[CrossRef](#)] [[PubMed](#)]
22. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. *J. Pharmacol. Toxicol. Methods* **2000**, *44*, 235–249. [[CrossRef](#)] [[PubMed](#)]
23. Benet, L.Z.; Hosey, C.M.; Ursu, O.; Oprea, T.I. BDDCS, the Rule of 5 and drugability. *Adv. Drug Deliv. Rev.* **2016**, *101*, 89–98. [[CrossRef](#)]
24. Dong, J.; Wang, N.-N.; Yao, Z.-J.; Zhang, L.; Cheng, Y.; Ouyang, D.; Lu, A.-P.; Cao, D.-S. ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. *J. Cheminform.* **2018**, *10*, 29. [[CrossRef](#)] [[PubMed](#)]
25. Yang, J.-F.; Wang, F.; Chen, Y.-Z.; Hao, G.-F.; Yang, G.-F. LARMD: Integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor. *Brief. Bioinform.* **2019**, *21*, 2206–2218. [[CrossRef](#)]
26. Verma, A.K.; Aggarwal, R. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. *Chem. Biol. Drug Des.* **2021**, *97*, 836–853. [[CrossRef](#)] [[PubMed](#)]
27. De Vita, S.; Chini, M.G.; Lauro, G.; Bifulco, G. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19). *RSC Adv.* **2020**, *10*, 40867–40875. [[CrossRef](#)] [[PubMed](#)]
28. Ahsan, T.; Sajib, A.A. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor. *Biochem. Biophys. Rep.* **2021**, *26*, 100982. [[CrossRef](#)]
29. de Oliveira, O.V.; Rocha, G.B.; Paluch, A.S.; Costa, L.T. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. *J. Biomol. Struct. Dyn.* **2020**, *39*, 3924–3933. [[CrossRef](#)]
30. Choudhary, S.; Malik, Y.S.; Tomar, S. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach. *Front. Immunol.* **2020**, *11*, 1664. [[CrossRef](#)]
31. Mahdian, S.; Ebrahim-Habibi, A.; Zarrabi, M. Drug repurposing using computational methods to identify therapeutic options for COVID-19. *J. Diabetes Metab. Disord.* **2020**, *19*, 691–699. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.